CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Conditions

Alzheimer's Disease

Phase III

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose.

  • Trial with
    F. Hoffman-La Roche Ltd
  • Start Date
    08/17/2016
  • End Date
    08/30/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Carol Gunnoud

  • Last Updated
    06/22/2018
  • Study HIC
    #1601017095